When innovation outpaces regulations: The legal challenges for direct‐to‐patient supply of investigational medicinal products
Open Access
- 13 August 2021
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 88 (3) , 1115-1142
Abstract
Aims: We profile the lack of specific regulation for direct‐to‐patient postal supply (DTP) of clinical trial medications (investigational medicinal products, IMPs) calling for increased efficiency of patient‐centred multi‐country remote clinical trials.Methods: Questionnaires emailed to 28 European Economic Area (EEA) Medical Product Licensing Authorities (MPLAs) and Swissmedic MPLA were analysed in 2019/2020. The questionnaire asked whether DTP of IMPs was legal, followed by comparative legal analysis profiling relevant national civil and criminal liability provisions in 30 European jurisdictions (including The Netherlands), finally summarising accessible COVID‐19‐related guidance in searches of 30 official MPLA websites in January 2021.Results: Twenty MPLAs responded. Twelve consented to response publication in 2021. DTP was not widely authorised, though different phrases were used to explain this. Our legal review of national laws in 29 EEA jurisdictions and Switzerland did not identify any specific sanctions for DTP of IMPs; however, we identified potential national civil and criminal liability provisions. Switzerland provides legal clarity where DTP of IMPs is conditionally legal. MPLA webpage searches for COVID‐19 guidance noted conditional acceptance by 19 MPLAs.Conclusions: Specific national legislation authorising DTP of IMPs, defining IMP categories, and conditions permitting the postage and delivery by courier in an EEA‐wide clinical trial, would support innovative patient‐centred research for multi‐country remote clinical trials. Despite it appearing more acceptable to do this between EU Member States, provided each EU MPLA and ethics board authorises it, temporary Covid‐19 restrictions in national Good Clinical Practice (GCP) guidance discourages innovative research into the safety and effectiveness of clinical trial medications.Keywords
Funding Information
- University of Dundee
This publication has 13 references indexed in Scilit:
- Managing oncology clinical trials during COVID-19 pandemicContemporary Clinical Trials Communications, 2020
- Challenges to sovereign ambitions: forces of convergence and divergence within the global pharmaceutical sector and the UK's withdrawal from the European UnionHealth Economics, Policy and Law, 2020
- Recommendations from national regulatory agencies for ongoing cancer trials during the COVID-19 pandemicThe Lancet Oncology, 2020
- Applying Blockchain Technology to Enhance Clinical Trial Recruitment.2020
- Does the provision of a DVD-based audio-visual presentation improve recruitment in a clinical trial? A randomised trial of DVD trial invitationsBMC Medical Research Methodology, 2019
- A novel drug management system in the Febuxostat versus Allopurinol Streamlined Trial: A description of a pharmacy system designed to supply medications directly to patients within a prospective multicenter randomised clinical trialClinical Trials, 2016
- Patient centric approach for clinical trials: Current trend and new opportunitiesPerspectives in Clinical Research, 2015
- Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemiaBMJ Open, 2014
- Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the member states relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use.2005
- Impact of the European Clinical Trials Directive on academic clinical research.2004